Pemphigus vulgaris (PV) is a rare immune-mediated skin disorder, typically occurring in middle-aged and older adults, that involves painful blistering of the skin and mucous membranes. While many patients are well controlled on systemic corticosteroid treatment, steroid-sparing therapy can be desirable for treating moderate to severe forms of the disease, and rituximab is one such agent to show promise in this indication.
Pemphigus vulgaris (PV) is a rare immune-mediated skin disorder, typically occurring in middle-aged and older adults, that involves painful blistering of the skin and mucous membranes. The disease has a relapsing and remitting course that can, in severe instances, be life-threatening. While many patients are well controlled on systemic corticosteroid treatment, steroid-sparing therapy can be desirable for treating moderate to severe forms of the disease, and rituximab is one such agent to show promise in this indication.
A recent, single-center, retrospective, case-control study reported on 40 patients with PV, treated at Duke University from 1999 to 2015, who required steroids plus conventional adjuvant therapy with agents such as mycophenolate mofetil, azathioprine, adalimumab, or infliximab (n = 27), or steroids and conventional therapy followed by rituximab (n = 13).
The group who received rituximab was able to reduce median monthly prednisone intake from pre-rituximab levels of 658.6 mg per month (interquartile range [IQR], 600.0-724.8) to 177.2 mg per month (IQR, 97.3-309.5) after starting rituximab.
There was no difference in monthly prednisone intake between the conventional therapy group and the rituximab group after treatment, but the patients who received conventional treatment only had significantly lower monthly prednisone intake (141 mg per month; IQR, 79.3-428.8) versus the pre-rituximab patients. There was no difference in the likelihood of being able to discontinue prednisone between the patient groups.
Additionally, patients who received rituximab had lower numbers of infections, hospital admissions, and emergency department visits per year after initiating rituximab.
Between the patients receiving conventional treatment alone and those receiving rituximab, there was no difference in the likelihood of complete remission, but those who received rituximab gained remission in a median time period of 6 months, while those who received conventional treatments gained remission after a median of 10.7 months.
“Rituximab may facilitate remission by a different, more efficient mechanism compared to [conventional therapy] as it decreased prednisone intake dramatically and significantly in the [rituximab] group despite their more severe disease,” write the authors, who add that even those who respond well to conventional drugs may benefit from earlier intervention with rituximab in terms of fewer infections, hospitalizations, laboratory draws, and clinic visits.
Reference
AgarwalA, Hall RP, Bañez LL, Cardones AR. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: a retrospective analysis [published online September 25, 2018]. PLOS One. https://doi.org/10.1371/journal.pone.0198074.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.